Hemogenyx Pharmaceuticals Plc (HOPHF)
OTC PINK OTC PINK Primary Summary
HOPHF Chart
Hemogenyx gains as first adult dose cohort is completed
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has completed the first adult dose cohort in its ongoing Phase I clinical trial for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia. "Completing the first adult dose cohort is a major achievement in our Phase I trial of HG-CT-1," said Hemogenyx chief executive Dr. Vladislav Sandler.
Hemogenyx Pharmaceuticals secures £709k of new investment
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has secured £709,200 in fresh investment from an institutional backer keen to support its ongoing clinical trials. The funding, at £1.80 per share, will help advance the company's experimental cancer treatment, HG-CT-1, which is being tested on patients with a hard-to-treat form of leukaemia called relapsed/refractory acute myeloid leukaemia.
Hemogenyx takes major step with AML treatment - ICYMI
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr. Vladislav Sandler talked with Proactive about the company's recent milestone—the first human dose of its proprietary CAR-T cell therapy, HG-CT-1, for treating relapsed refractory acute myeloid leukemia (AML) in adults.
Hemogenyx Pharmaceuticals Plc (HOPHF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hemogenyx Pharmaceuticals Plc ever had a stock split?
Hemogenyx Pharmaceuticals Plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Vladislav Sandler Ph.D. CEO | OTC PINK Exchange | GB00BYX3WZ24 ISIN |
| GB Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Hemogenyx Pharmaceuticals Plc is a pioneering biotechnology entity engrossed in the inception, evolution, and eventual market launch of therapeutic solutions aimed at treating hematological diseases. Established in 2012 and anchored in London, United Kingdom, this preclinical-stage company is carving a niche in the medical realm by addressing some of the most pressing needs within the bone marrow/hematopoietic stem cell (BM/HSC) transplant field. With a keen focus on cutting-edge scientific research and development, Hemogenyx Pharmaceuticals Plc is on a quest to revolutionize the treatment landscape for blood diseases through its innovative product pipeline.
Products and Services
- CDX Bi-specific Antibody
Targeting the severe and often relentless form of acute myeloid leukaemia (R/R AML), the CDX bi-specific antibody stands out as a beacon of hope. This therapeutic innovation is designed to address the challenges presented by relapsed or refractory cases of AML, offering a potential lifeline to patients in dire need of effective treatment options.
- HEMO-CAR-T Therapy
A testament to the company's commitment to leveraging advanced therapeutic modalities, the HEMO-CAR-T therapy utilizes chimeric antigen receptor T-cells. This cutting-edge approach not only identifies but also eradicates AML-derived cells both in vitro (lab settings) and in vivo (within the body), presenting a game-changing strategy in the battle against AML.
- Human Postnatal Hematopoietic Endothelial Cells
In the realm of stem cell therapy, Hemogenyx Pharmaceuticals Plc is making significant strides with its Human Postnatal Hematopoietic Endothelial Cells. This product represents a groundbreaking stem cell therapy aimed at BM/HSC transplants, offering new avenues for treatment and hope to patients undergoing bone marrow transplants.
